How much does Ingrezza cost and will insurance cover it?

Q: How much does Ingrezza cost and will insurance cover it?

Ingrezza costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength, or an annual cost of $102,973 to $113,126 per year; however, most people do not pay this amount. People with commercial insurance may qualify for a $0 copay for each Ingrezza prescription through the INBRACE Support Program and approximately 46% of Medicare Part D and Medicare Advantage plans cover Ingrezza. For people with Medicaid, most states require prior authorization for Ingrezza and the satisfaction of certain criteria before it can be funded.

Medically reviewed by Carmen Pope, BPharm. Last updated on March 15, 2024.

Official answer

by Drugs.com

Ingrezza (valbenazine) costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength. This works out to be around $282 for each 40mg capsule and around $310 for every 80mg capsule. This cost depends on the pharmacy you visit and is based on using the Drugs.com discount card. This price is for cash paying customers and is not valid with insurance plans.

This works out to an annual cost of $102,973 to $113,126 per year, but most people do not pay this amount.

Ingrezza is also available as a one-month free trial for new patients, through the Ingrezza Start program. For more information, call 1-84-INGREZZA (1-844-647-3992) 8am to 8pm EST, Monday through Friday.

People with commercial insurance (non-government funded) may qualify for a $0 copay for each monthly Ingrezza prescription through the Ingrezza savings card provided through the INBRACE Support Program. $10 a month or less is what most patients on this type of insurance pay for Ingrezza.

If you have Medicare your copay costs may range from $59 to the full cost of the drug, after the deductible stage. Approximately 46% of Medicare Part D and Medicare Advantage plans cover Ingrezza.

If you have Medicaid most states require that you (or your physician) get prior authorization before filling your prescription for Ingrezza. Without prior approval, Medicaid may not cover this drug. In addition, Ingrezza is usually only approvable for Medicaid members aged 18 years of age or older with a diagnosis of moderate to severe TD caused by the use of a dopamine receptor blocking agent (eg, antipsychotics, metoclopramide) when other treatments, such as clonazepam, amantadine, tetrabenazine, or deutetrabenazine have been ineffective or not tolerated and the medication is prescribed by or in consultation with a specialist, such as a neurologist or a psychiatrist. Some costs may also be covered for adults with chorea associated with Huntington’s disease (HD), a hereditary progressive neurodegenerative disorder. The actual cost you pay varies by state.

Ingrezza mechanism of action: How does it work?

Experts aren’t sure exactly how Ingrezza works but suggest it blocks a protein transporter called vesicular monoamine transporter 2 (VMAT2), which is responsible for regulating the uptake of neurotransmitters such as dopamine. The abnormal functioning of dopamine is thought to be a cause of tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). By blocking VMAT2, Ingrezza reduces the uptake of dopamine, causing a decrease in symptoms of TD and chorea. Continue reading

Can Ingrezza capsules be opened?

Ingrezza Sprinkle capsules can be opened and sprinkled on soft food, such as applesauce, yogurt or pudding before swallowing. Do not chew the granules before swallowing. If you use the regular Ingrezza capsule that is swallowed and not sprinkled, do not open, cut, crush or split the capsule without your doctor’s advice. Continue reading

What condition is Ingrezza used to treat?

Ingrezza (valbenazine) capsules and Ingrezza Sprinkle capsules are approved for the treatment of adults with tardive dyskinesia and with chorea associated with Huntington's disease (HD), two types of involuntary movement disorders. Ingrezza is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor. Continue reading

Drug information

Ingrezza Information for Consumers
Ingrezza prescribing info & package insert (for Health Professionals)
Side Effects of Ingrezza (detailed)
Ingrezza user reviews (19)

Related support groups

Ingrezza (9 questions, 19 members)
Tardive Dyskinesia (35 questions, 173 members)

Medical Disclaimer